Participants agreed on the need for laboratory directors to work closely with physicians and clinical pharmacists to develop guidelines for establishing and handling critical drug concentrations.
There was a degree of controversy regarding the most appropriate phlebotomy tube for TDM samples. Although there was concern about scientific documentation, there seemed to be agreement that phlebotomy tubes with silicon "barrier" gels should be avoided.
There was discussion on the degree of analytical precision required and also on the amount and type of cross-reactivity that can be tolerated. In addition, there was a fair amount of discussion of when analyses need to be available Stat and how rapid routine and Stat analyses must be for various patient populations.
One of the most contentious discussions was on the need for free drug measurements. From the discussion came the acknowledgment that, although free drugs concentrations should be the most accurate reflection of drug available at the cellular level, there is insufficient documentation that free drug measurements make any significant difference in treatment for cardiac drugs. In addition, there is a sparsity of good data to establish useful therapeutic ranges for free drug measurements. From the discussion came the recommendation that additional research needs to be performed on the clinical efficacy of free drug measurements.
As laboratory scientists and physicians grapple with new clinical effectiveness regulations, the guidelines in this SOLP, particularly those addressing appropriate clinical indications, should serve as an excellent foundation for that effort. Recommendations for all these areas were reviewed and discussed by meeting participants.
